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and its homozygosity (RR = 23.02, p < 0.005) was more 
frequent among patients than healthy individuals. no sig-
nificant association was observed for either other polymor-
phisms studied or Il-17 levels.
Conclusions thus, the rs763780 IL-17F polymorphism 
was found to be associated with predisposition to aMl in 
the Polish population.
Keywords Il-17 · gene polymorphism · Disease 
association · acute myeloid leukemia
Introduction
acute myeloid leukemia (aMl) is a life-threatening 
hematopoietic stem cell neoplasm characterized by bone 
marrow infiltration by leukemic cells that suppress nor-
mal hematopoiesis, frequently resulting in fatal infection, 
bleeding or organ infiltration, with or without leukocyto-
sis (lowenberg et al. 1999; estey and Dohner 2006). the 
etiology of aMl is heterogeneous and complex, but it is 
widely accepted that both environmental and genetic fac-
tors play significant roles in the development of aMl.
Recent studies have suggested that th17 cells may play 
an important role in patients with aMl [discussed by li 
et al. (2012)]. It has been reported that the th17 cell fre-
quencies or levels of Il-17 and its related cytokines were 
different between normal cells and malignant aMl cells, 
suggesting that th17 cells might be involved in aMl 
pathogenesis (Wu et al. 2009; abousamra et al. 2013). It 
has also been observed that the increased th17 cell fre-
quencies were reduced when patients achieved complete 
remission (CR) after chemotherapy, suggesting that meas-
urement of th17 cell frequencies may have clinical value 
in evaluation of the therapeutic effect (Wu et al. 2009).
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share strong homology, and surface expression of the Il-23 
receptor (Il-23R). the present study aimed to determine 
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within the IL-17A, IL-17F and IL-23R genes and disease 
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the plasma Il-17 levels in patients was analyzed.
Methods For this purpose, 187 individuals of Polish 
origin including 62 aMl patients and 125 healthy con-
trols were typed for IL-17A (rs2275913; g-197a), IL-17F 
(rs763780; a7488g; His161arg) and IL-23R (rs11209026, 
g1142a; arg381gln) alleles.
Results the rs763780 IL-17F polymorphism appeared 
to be associated with susceptibility to the disease. the 
presence of the minor (G) variant (RR = 4.76, p < 0.001) 
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the hallmark of the th17 subset is the production of 
interleukin Il-17a and Il-17F, which share strong homol-
ogy, and surface expression of the Il-23 receptor (Il-23R) 
(Hot et al. 2011). Il-23 is essential for the differentiation 
of th17 cells and plays a key role in the development of 
pathogenic th17 cells that produce the cytokine Il-17, 
which induces the production of several pro-inflamma-
tory cytokines, such as tnF-a and Il-6, and chemokines 
(aggarwal et al. 2003; Bettelli et al. 2008; McKenzie et al. 
2006). Il-23 and Il-21 induce the orphan nuclear recep-
tor RORγt, which in synergy with Stat3 promotes Il-17 
expression (nurieva et al. 2007).
the present study aimed to determine the association 
between the polymorphic features located within the IL-
17A, IL-17F and IL-23R genes and disease susceptibil-
ity, progression and response to therapy. For this purpose, 
patients with aMl and healthy individuals were typed 
for the IL-17A (rs2275913; g-197a), IL-17F (rs763780; 
a7488g; His161arg) and IL-23R (rs11209026, g1142a; 
arg381gln) alleles. In addition, the relationship between 
the polymorphic variants of the Il-17 genes and plasma 
Il-17 levels were analyzed.
Materials and methods
Patients and controls
Sixty-two adult patients (24 females and 38 males, median 
age 52 years, range 19–80 years) with aMl were investi-
gated. Patients with acute promyelocytic leukemia were 
excluded.
In addition 125 Polish healthy individuals of both sexes 
(female/male: 63/62) served as controls.
IL-17A, IL-17F and IL-23R genotyping
three biallelic polymorphisms were studied: IL-17A 
(rs2275913; g-197a), IL-17F (rs763780; a7488g; 
His161arg) and IL-23R (rs11209026, g1142a).
the IL-17F (rs763780; a7488g) polymorphism was 
analyzed using a polymerase chain reaction restriction 
fragment length polymorphism (PCR–RFlP) assay, 
which amplified a fragment of the promoter region of 
the gene using primers as previously described [15] (for-
ward: 5′-gtt CCC atC Cag Caa gag aC-3′ and 
reverse: 5′-agC tgg gaa tgC aaa Caa aC-3′). 
the PCR conditions were as follows: 94 °C for 3 min; 
35 cycles at 94 °C for 30 s, 60 °C for 30 s and 72 °C for 
30 s; and a final elongation step at 72 °C for 7 min. the 
PCR products were analyzed by electrophoresis in 2 % 
agarose gel stained with ethidium bromide and visual-
ized under UV light (Uvitec). the PCR products were 
digested with the NlaIII restriction endonuclease (new 
england Biolabs Inc.) and analyzed in 2 % agarose gel. 
three patterns were observed following digestion and 
electrophoresis: a single 412 bp fragment (individuals 
homozygous for the IL-17F G allele, lacking the NlaIII 
site), three fragments of 412, 288 and 124 bp in length 
(heterozygous individuals) or two fragments of 288 
and 124 bp (individuals homozygous for the IL-17F A 
allele).
PCR amplifications for the IL-17F gene polymor-
phism studies were carried out in the 2720 thermal Cycler 
(applied Biosystems, Foster City, USa).
the IL-17A (rs2275913; g-197a) and IL-23R 
(rs11209026, g1142a) alleles were determined by real-
time PCR amplifications, and analysis of the typing 
results was performed using a Roche lightCycler 480 
instrument. the lightSniP (rs2275913) assay designed 
by tIB MOlBIOl (gmbH, Berlin, germany) or taqMan 
SnP genotyping assay (rs11209026) (life technolo-
gies) was used for detection of IL-17A and IL-23R alleles, 
respectively.
enzyme-linked immunosorbent assay (elISa) for plasma 
Il-17
Plasma samples were taken from all the patients before 
chemotherapy was administered. In addition, 20 out of 62 
patients were analyzed again after achieving CR. Il-17 
levels were measured by enzyme-linked immunoassay 
(elISa) (R&D Systems, USa) following the manufactur-
er’s instruction. analyses and calibrations were carried out 
in duplicate. Intra- and interassay variations were within 
the range given by the manufacturer.
Minimum detectable level of Il-17 was less than 15 pg/
ml. ten samples from healthy volunteers (4 females and 
6 males, median age 40 years; range 35–60 years) were 
evaluated as the control. the data were analyzed using the 
Mann–Whitney U test.
Statistical analysis
genotype and allele frequencies were compared between 
the study groups by the χ2 test with yates correction or 
Fisher’s exact test when necessary using Statistica 5.5 for 
Windows software. the odds ratio/relative risk (RR) was 
calculated by Haldane’s modification of Woolf’s method 
and the significance of its deviation from unity was esti-
mated by Fisher’s exact test. all p values were corrected 
(pc) for the number of comparisons. the Il-17 plasma lev-
els were analyzed using the Mann–Whitney U test. Proba-
bility values <0.05 were considered statistically significant 
and those between 0.05 and 0.1 as indicative of a trend.
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Results
Distribution of IL-17A and IL-23R alleles and genotypes 
in aMl patients and controls
there were no significant differences in the distributions of 
the IL-17A and IL-23R alleles and genotypes. the IL-17A 
(rs2275913) GG, GA and AA genotypes were detected in 
23 (37.1 %), 25 (40.3 %) and 14 (22.6 %) patients, and in 
38 (30.4 %), 67 (53.6 %) and 20 (16 %) controls, respec-
tively. Only a slight tendency toward a higher frequency 
of the IL-17A heterozygosity was observed (RR = 1.73, 
p = 0.091, table 1). the allelic frequencies of the A vari-
ant of the IL-17A gene were 0.427 and 0.428, in patients 
and controls, respectively, which closely resemble those 
observed in other studies of healthy european populations.
the IL-23R A variant was very rarely detected. none 
of the individuals tested was carrying the IL-23R AA 
homozygous genotype. Fifty-five patients (88.7 %) and 111 
(88.8 %) healthy individuals were homozygous for the IL-
23R (rs11209026) G wild-type allele. there were only 7 
(11.3 %) and 14 (11.2 %) GA heterozygotes among aMl 
patients and controls, respectively (table 1). the allelic 
frequency of the A variant was 0.056 in both patients and 
controls.
associations with predisposition to aMl and progression 
of the disease, impact of the IL-17F polymorphism
among the polymorphisms studied, the IL-17F (a7488g) 
polymorphic variants were found to be associated with 
aMl. the presence of the IL-17F G allele was more fre-
quently observed among patients than healthy individuals. 
this allelic variant was detected in 20 out of 62 (32.3 %) 
patients with aMl and only in 11 out of 125 (8.8 %) con-
trols (RR = 4.76, pc < 0.001). the allelic frequencies of 
the G variant of the IL-17F gene were 0.202 and 0.044, in 
patients and controls, respectively.
an even stronger association was observed when the 
IL-17F GG homozygous genotype was considered. IL-17F 
GG homozygosity was detected in five patients and none of 
the controls (RR = 23.02, pc < 0.05; table 1; Fig. 1).
Relationships between the IL-17F polymorphic variants 
and Il-17 plasma levels
Il-17 was detected in 9 out of 62 aMl patients at diag-
nosis (range, mean ± SD: 1.37–19.10, 8.8 ± 7.19 pg/ml), 
2 out of 19 in aMl in CR, and 2 out of 10 in the control 
group (at the level of 1.4 pg/ml in these 4 latter samples).
no significant relationships were observed with respect 
to the Il-17 plasma levels and disease progression (CR) or 
any of the polymorphisms studied.
no correlation between the polymorphisms studied 
and response to therapy or survival
none of the polymorphisms studies were observed to be 
associated with response to therapy or patient survival. 
all genotypes segregated similarly in alive and fatal cases. 
there was no significant difference in the distribution of 
IL-17A, IL-17F and IL-23R genotypes between patients 
who achieved or did not achieve CR.
Discussion
In the present study, we wanted to find out whether poly-
morphic variants of the genes coding for Il-17a, Il-17F 
and receptor for Il-23 (as hallmarks of th17 cells) could be 
associated with susceptibility to acute myeloid leukemia, dis-
ease progression and/or response to therapy. In addition, the 
relationship between the polymorphic variants of the Il-17 
encoding genes and the plasma Il-17 levels was analyzed.
among the three biallelic polymorphisms considered, 
only the IL-17F (a7488g) polymorphism was found to be 
Table 1  Distribution of the IL-17A, IL-17F and IL-23R alleles and 
genotypes in Polish patients with aMl and healthy individuals
the IL-17F polymorphism was associated with predisposition to 
aMl
a
 RR = 4.76, p = 0.0009, pc = 0.0027
b
 RR = 23.02, p = 0.0036, pc = 0.0108
Polymorphism aMl patients Controls
n (%) n (%)
IL-17A (g-197a) rs2275913
 GG 23 37.1 38 30.4
 GA 25 40.3 67 53.6
 AA 14 22.6 20 16.0
 G 48 77.4 105 84.0
 A 14 62.9 87 69.6
IL-17F (a7488g) rs763780
 AA 42 67.7 114 91.2
 AG 15 24.2 11 8.8
 GG 5b 8.1 0b 0
 A 57 91.9 125 100
 G 20a 32.3 11a 8.8
IL-23R (g1142a) rs11209026
 GG 55 88.70 111 88.8
 GA 7 11.3 14 11.2
 AA 0 0 0 0
 G 62 100 125 100
 A 7 11.3 14 11.2
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associated with predisposition to aMl. the presence of the 
IL-17F G variant and its homozygosity were significantly 
more frequently observed among patients than healthy 
individuals. this is a novel observation not previously 
described.
Interestingly, Kawaguchi et al. observed the functional 
consequences of this IL-17F polymorphism and suggested 
that the Il-17 expression and activity may be suppressed 
in carriers of the rare G allele (Kawaguchi et al. 2006). 
However, this effect was not observed in our present study. 
as suggested by Kawaguchi et al., we might expect that 
patients carrying this allelic variant would be characterized 
by lower levels of Il-17. However, we found no signifi-
cant differences in the Il-17 plasma levels between aMl 
patients with different IL-17F genotypes.
as for the rs2275913 IL-17A polymorphism, espinoza 
et al. demonstrated that in vitro stimulated t cells from 
healthy individuals possessing the 197A allele produced 
significantly more Il-17 than those without the 197A allele 
(espinoza et al. 2011). However, similarly as for the IL-17F 
polymorphism, no significant relationships between the IL-
17A genotypes and Il-17 plasma levels were observed in 
the present study.
Moreover, as previously found, no difference was 
detected between patients and controls with respect to the 
Il-17 plasma levels (Wrobel et al. 2003).
notably, the differences in Il-17 concentrations and 
frequencies of Il-17 producing cells have been previously 
reported in the literature, suggesting that their increase may 
have an adverse effect. For example, Wu et al. observed 
significantly increased frequencies of th17 cells in periph-
eral blood samples from untreated patients with aMl, 
compared with those from healthy volunteers (Wu et al. 
2009). they also found that increased Il-17 concentrations 
accompanied the increased th17 cell frequencies in these 
patients and that the increased th17 cell frequencies were 
reduced when patients achieved CR after chemotherapy. 
In a more recent report of abousamra et al., who studied 
patients with acute myeloid (aMl) and acute lymphoblas-
tic leukemia (all), circulating th17 cells were increased 
in patients with acute leukemias and were significantly 
higher than in healthy controls. In these patients, th17 cells 
were reduced significantly in those who achieved CR after 
induction therapy (abousamra et al. 2013). also tian et al. 
observed higher frequencies of th17 cells and a significant 
decrease in Il-17 concentration in patients with t-all 
(both newly diagnosed and in CR) than in controls (tian 
et al. 2013).
It is of note that the results of the three latter studies 
consider patients of Chinese (Wu et al. 2009; tian et al. 
2013) or egyptian (abousamra et al. 2013) origin. thus, 
the differences in the results could be attributed to the com-
positions of patient groups studied, including the lack of an 
association between the IL-17F variants and Il-17 plasma 
levels [reported by Kawaguchi et al. (2006) for the Japa-
nese population].
to our knowledge, there are no published data on the 
role of the IL-17A, IL-17F or IL-23R polymorphisms in 
aMl; thus, our report presents novel observations not pre-
viously described. We found that they significantly con-
tribute to the disease susceptibility in Polish patients with 
aMl. Obviously, these results should be confirmed in a 
more extended study, including patients from other centers.
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